SCHEMBL5714517

SCHEMBL5714517

O=C(Oc1ccc(CCSc2ccncc2)cc1)N1CCN(c2ccc(Cl)cn2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 5/20 0.46
ME1 P48163 5/20 0.46
ME3 Q16798 5/20 0.46
TRPA1 O75762 2/20 0.45
PANK3 Q9H999 2/20 0.44
TRPV1 Q8NER1 1/20 0.43
TMEM97 Q5BJF2 2/20 0.40
SIGMAR1 Q99720 2/20 0.40
GPR119 Q8TDV5 1/20 0.40
DRD2 P14416 3/20 0.40
DRD4 P21917 2/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
HTR1A P08908 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR7 P34969 1/20 0.40
DRD3 P35462 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714729 0.89 ME2 (0.46) ME2ME1ME3TRPA1PANK3
SCHEMBL5715446 0.89 PANK3 (0.44) ME2ME1ME3PANK3TRPV1
SCHEMBL5714635 0.88 PANK3 (0.42) ME2ME1ME3PANK3TRPV1
SCHEMBL5714815 0.88 HRH3 (0.42) ME2ME1ME3PANK3TRPV1
SCHEMBL5714506 0.88 TRPA1 (0.49) ME2ME1ME3TRPA1PANK3
SCHEMBL5714344 0.86 SMN1; SMN2 (0.54) TRPA1TRPV1MAPT
SCHEMBL5715038 0.86 ME2 (0.43) ME2ME1ME3TRPA1PANK3
SCHEMBL5714531 0.86 TRPA1 (0.48) ME2ME1ME3TRPA1PANK3
SCHEMBL5714398 0.86 ALDH1A1 (0.52) TRPV1NPC1GAAMAPTTSHR
SCHEMBL5904307 0.84 ALDH1A1 (0.45) ME2ME1ME3TRPA1PANK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC ME2 854/4885ME1 2914/4885ME3 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.